Beaumont K, Cheung A K, Geller M L, Fanestil D D
Life Sci. 1983 Oct 3;33(14):1375-84. doi: 10.1016/0024-3205(83)90820-2.
Several endogenous substances that inhibit central-type benzodiazepine (BZD) receptor binding have recently been identified. We have found that ultrafiltrates of human uremic plasma, normal plasma, and urine contain competitive inhibitors of peripheral-type benzodiazepine receptors. Using urine as source, we have partially purified a peripheral-type BZD receptor inhibitor(s) by adsorption to and selective elution from small octadecyl-silane (Sep-pak) columns and thin layer chromatography. The inhibitor has a 125-fold greater affinity for peripheral-type than central-type BZD receptors and has been purified 8000-fold from urine.
最近已鉴定出几种抑制中枢型苯二氮䓬(BZD)受体结合的内源性物质。我们发现,人尿毒症血浆、正常血浆和尿液的超滤物含有外周型苯二氮䓬受体的竞争性抑制剂。以尿液为来源,我们通过吸附到小十八烷基硅烷(Sep-pak)柱上并从其选择性洗脱以及薄层色谱法,部分纯化了一种外周型BZD受体抑制剂。该抑制剂对外周型BZD受体的亲和力比对中枢型BZD受体大125倍,并且已从尿液中纯化了8000倍。